Tags

Type your tag names separated by a space and hit enter

Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Metabolism. 2001 Jan; 50(1):112-9.M

Abstract

The distribution of apolipoprotein C-III (apoC-III) between high-density lipoprotein (HDL) and apoB-containing lipoproteins has been used in lipid-lowering angiographic trials to establish a link between impaired triglyceride (TG)-rich lipoprotein (TRL) metabolism and the progression of coronary artery disease. To investigate the extent to which plasma lipoprotein apoC-III levels reflect the presence in plasma of potentially atherogenic remnant lipoproteins, we studied 4 groups of subjects: (1) normolipidemic (NL, n = 10), (2) hypercholesterolemic (HC, type IIa, low-density lipoprotein cholesterol [LDL-C] > 3.4 mmol/L, n = 10), (3) hypertriglyceridemic (HTG, type IV, TG > 2.3 mmol/L, n = 10), and (4) combined hyperlipidemic (CHL, type IIb, TG > 2.3 mmol/L, LDL-C > 3.4 mmol/L, n = 10). The apoC-III level was measured in plasma lipoproteins separated either by density (ultracentrifugation) or by size (fast protein liquid chromatography [FPLC]), and was compared with 4 parameters reflecting remnant lipoprotein levels (ie, very-low-density lipoprotein cholesterol [VLDL-C], intermediate-density lipoprotein cholesterol [IDL-C], remnant-like particle cholesterol [RLP-C], and intermediate-sized lipoprotein [ISL] apoE). Our results demonstrate that (1) increased amounts of apoC-III associated with plasma VLDL, TRL, or apoB-containing lipoproteins (LpB), as well as increased levels of TRL remnant lipoproteins, are a characteristic of HTG patients rather than patients with increased LDL, and (2) plasma levels of apoC-III in VLDL, TRL, or LpB, as well as the HDL apoC-III to LpB apoC-III ratios, are strongly correlated with circulating levels of TRL, although these apoC-II parameters more closely reflect the balance between TRL TG production and lipolysis than the extent of plasma TRL remnant accumulation.

Links

Publisher Full Text

Authors+Show Affiliations

Marcoux C
Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada.
Tremblay M
No affiliation info available
Fredenrich A
No affiliation info available
Davignon J
No affiliation info available
Cohn JS
No affiliation info available

MeSH

AdultApolipoprotein C-IIIApolipoproteins CHumansHyperlipidemiasLipoproteinsLipoproteins, HDLLipoproteins, LDLLipoproteins, VLDLMaleMiddle AgedTriglycerides

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11172484

Citation

Marcoux, C, et al. "Lipoprotein Distribution of Apolipoprotein C-III and Its Relationship to the Presence in Plasma of Triglyceride-rich Remnant Lipoproteins." Metabolism: Clinical and Experimental, vol. 50, no. 1, 2001, pp. 112-9.
Marcoux C, Tremblay M, Fredenrich A, et al. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism. 2001;50(1):112-9.
Marcoux, C., Tremblay, M., Fredenrich, A., Davignon, J., & Cohn, J. S. (2001). Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism: Clinical and Experimental, 50(1), 112-9.
Marcoux C, et al. Lipoprotein Distribution of Apolipoprotein C-III and Its Relationship to the Presence in Plasma of Triglyceride-rich Remnant Lipoproteins. Metabolism. 2001;50(1):112-9. PubMed PMID: 11172484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. AU - Marcoux,C, AU - Tremblay,M, AU - Fredenrich,A, AU - Davignon,J, AU - Cohn,J S, PY - 2001/2/15/pubmed PY - 2001/3/3/medline PY - 2001/2/15/entrez SP - 112 EP - 9 JF - Metabolism: clinical and experimental JO - Metabolism VL - 50 IS - 1 N2 - The distribution of apolipoprotein C-III (apoC-III) between high-density lipoprotein (HDL) and apoB-containing lipoproteins has been used in lipid-lowering angiographic trials to establish a link between impaired triglyceride (TG)-rich lipoprotein (TRL) metabolism and the progression of coronary artery disease. To investigate the extent to which plasma lipoprotein apoC-III levels reflect the presence in plasma of potentially atherogenic remnant lipoproteins, we studied 4 groups of subjects: (1) normolipidemic (NL, n = 10), (2) hypercholesterolemic (HC, type IIa, low-density lipoprotein cholesterol [LDL-C] > 3.4 mmol/L, n = 10), (3) hypertriglyceridemic (HTG, type IV, TG > 2.3 mmol/L, n = 10), and (4) combined hyperlipidemic (CHL, type IIb, TG > 2.3 mmol/L, LDL-C > 3.4 mmol/L, n = 10). The apoC-III level was measured in plasma lipoproteins separated either by density (ultracentrifugation) or by size (fast protein liquid chromatography [FPLC]), and was compared with 4 parameters reflecting remnant lipoprotein levels (ie, very-low-density lipoprotein cholesterol [VLDL-C], intermediate-density lipoprotein cholesterol [IDL-C], remnant-like particle cholesterol [RLP-C], and intermediate-sized lipoprotein [ISL] apoE). Our results demonstrate that (1) increased amounts of apoC-III associated with plasma VLDL, TRL, or apoB-containing lipoproteins (LpB), as well as increased levels of TRL remnant lipoproteins, are a characteristic of HTG patients rather than patients with increased LDL, and (2) plasma levels of apoC-III in VLDL, TRL, or LpB, as well as the HDL apoC-III to LpB apoC-III ratios, are strongly correlated with circulating levels of TRL, although these apoC-II parameters more closely reflect the balance between TRL TG production and lipolysis than the extent of plasma TRL remnant accumulation. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/11172484/Lipoprotein_distribution_of_apolipoprotein_C_III_and_its_relationship_to_the_presence_in_plasma_of_triglyceride_rich_remnant_lipoproteins_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(01)36075-4 DB - PRIME DP - Unbound Medicine ER -